Ombitasvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin in real world hepatitis C patients

Table 1 Demographic and clinical characteristics of patients n (%)

Characteristic	Patients
Age
n	104
Mean (yr ± SD)	49.9 ± 10.5
Min, max (yr)	29.0, 78.0
Median (yr) (IQR)	51.5 (41.0, 58.2)
Gender
n	104
Female	46 (44.2)
Male	58 (55.8)
Ethnicity
n	104
Hispanic or Latino	48 (46.2)
Not Hispanic or Latino	56 (53.8)
Race
n	104
White	91 (87.5)
Black	11 (10.6)
Unknown	2 (2)
Current comorbidities
n	104
Hypertension	46 (44.2)
Obesity	35 (33.7)
Cirrhosis, Child-Pugh A	21 (20.2)
Hepatic steatosis	18 (17.3)
Diabetes mellitus, type II	17(16.3)
Hyperlipidemia	17 (16.3)
Chronic kidney disease	3 (3)
Coronary artery disease	3 (3)
Atherosclerosis	1 (1)
Congestive heart failure	1 (1)
HIV	1 (1)
Genotype
n	100
GT1a	86 (86)
GT1b	14 (14)
Prior HCV treatment
n	100
IFN	2 (2)
IFN+RBV	3 (3)
PegIFN	1 (1)
PegIFN+RBV	10 (10)

SD: Standard deviation; IQR: Interquartile range; GT1: Genotype 1; IFN: Interferon; PegIFN: Pegylated interferon; RBV: Ribavirin.

Table 2 Adverse events reported during the HEARTLAND study

Most common adverse events	Patients reporting AE (n = 100)
Fatigue	12 (12%)
Headache	10 (10%)
Insomnia	9 (9%)
Diarrhea	8 (8%)
Anemia	6 (6%)
Nausea	6 (6%)
Pruritus	5 (5%)
Rash	4 (4%)
Upper respiratory infection	3 (3%)
Urinary tract infection	3 (3%)

AE: Adverse event.

Table 3 Mean short form 36 version 2 scores using the normative based scores

	End of treatment	Baseline	P value
	(n = 67)	(n = 67)	(Paired)
Physical functioning	45.6 ± 11.3	44.4 ± 11.0	0.3389
Physical	45.3 ± 10.8	42.2 ± 10.4	0.0152
Bodily pain	46.3 ± 12.0	43.9 ± 11.2	0.1103
General health	49.0 ± 10.8	44.6 ± 10.5	0.0004
Vitality	50.4 ± 11.9	46.0 ± 10.6	0.0066
Social functioning	45.4 ± 11.9	42.7 ± 12.1	0.0530
Emotional	45.2 ± 12.1	41.8 ± 11.4	0.0272
Mental Health	46.6 ± 12.6	44.1 ± 10.4	0.0287
Physical component summary	46.8 ± 10.7	44.4 ± 9.1	0.0404
Mental component summary	47.1 ± 13.7	43.6 ± 11.6	0.0112